E-cadherin breast tumor expression, risk factors and survival
Standard
E-cadherin breast tumor expression, risk factors and survival : Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium. / Horne, Hisani N; Oh, Hannah; Sherman, Mark E; Palakal, Maya; Hewitt, Stephen M; Schmidt, Marjanka K; Milne, Roger L; Hardisson, David; Benitez, Javier; Blomqvist, Carl; Bolla, Manjeet K; Brenner, Hermann; Chang-Claude, Jenny; Cora, Renata; Couch, Fergus J; Cuk, Katarina; Devilee, Peter; Easton, Douglas F; Eccles, Diana M; Eilber, Ursula; Hartikainen, Jaana M; Heikkilä, Päivi; Holleczek, Bernd; Hooning, Maartje J; Jones, Michael; Keeman, Renske; Mannermaa, Arto; Martens, John W M; Muranen, Taru A; Nevanlinna, Heli; Olson, Janet E; Orr, Nick; Perez, Jose I A; Pharoah, Paul D P; Ruddy, Kathryn J; Saum, Kai-Uwe; Schoemaker, Minouk J; Seynaeve, Caroline; Sironen, Reijo; Smit, Vincent T H B M; Swerdlow, Anthony J; Tengström, Maria; Thomas, Abigail S; Timmermans, A Mieke; Tollenaar, Rob A E M; Troester, Melissa A; van Asperen, Christi J; van Deurzen, Carolien H M; Van Leeuwen, Flora F; Van't Veer, Laura J; García-Closas, Montserrat; Figueroa, Jonine D.
In: SCI REP-UK, Vol. 8, No. 1, 26.04.2018, p. 6574.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - E-cadherin breast tumor expression, risk factors and survival
T2 - Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium
AU - Horne, Hisani N
AU - Oh, Hannah
AU - Sherman, Mark E
AU - Palakal, Maya
AU - Hewitt, Stephen M
AU - Schmidt, Marjanka K
AU - Milne, Roger L
AU - Hardisson, David
AU - Benitez, Javier
AU - Blomqvist, Carl
AU - Bolla, Manjeet K
AU - Brenner, Hermann
AU - Chang-Claude, Jenny
AU - Cora, Renata
AU - Couch, Fergus J
AU - Cuk, Katarina
AU - Devilee, Peter
AU - Easton, Douglas F
AU - Eccles, Diana M
AU - Eilber, Ursula
AU - Hartikainen, Jaana M
AU - Heikkilä, Päivi
AU - Holleczek, Bernd
AU - Hooning, Maartje J
AU - Jones, Michael
AU - Keeman, Renske
AU - Mannermaa, Arto
AU - Martens, John W M
AU - Muranen, Taru A
AU - Nevanlinna, Heli
AU - Olson, Janet E
AU - Orr, Nick
AU - Perez, Jose I A
AU - Pharoah, Paul D P
AU - Ruddy, Kathryn J
AU - Saum, Kai-Uwe
AU - Schoemaker, Minouk J
AU - Seynaeve, Caroline
AU - Sironen, Reijo
AU - Smit, Vincent T H B M
AU - Swerdlow, Anthony J
AU - Tengström, Maria
AU - Thomas, Abigail S
AU - Timmermans, A Mieke
AU - Tollenaar, Rob A E M
AU - Troester, Melissa A
AU - van Asperen, Christi J
AU - van Deurzen, Carolien H M
AU - Van Leeuwen, Flora F
AU - Van't Veer, Laura J
AU - García-Closas, Montserrat
AU - Figueroa, Jonine D
PY - 2018/4/26
Y1 - 2018/4/26
N2 - E-cadherin (CDH1) is a putative tumor suppressor gene implicated in breast carcinogenesis. Yet, whether risk factors or survival differ by E-cadherin tumor expression is unclear. We evaluated E-cadherin tumor immunohistochemistry expression using tissue microarrays of 5,933 female invasive breast cancers from 12 studies from the Breast Cancer Consortium. H-scores were calculated and case-case odds ratios (OR) and 95% confidence intervals (CIs) were estimated using logistic regression. Survival analyses were performed using Cox regression models. All analyses were stratified by estrogen receptor (ER) status and histologic subtype. E-cadherin low cases (N = 1191, 20%) were more frequently of lobular histology, low grade, >2 cm, and HER2-negative. Loss of E-cadherin expression (score < 100) was associated with menopausal hormone use among ER-positive tumors (ever compared to never users, OR = 1.24, 95% CI = 0.97-1.59), which was stronger when we evaluated complete loss of E-cadherin (i.e. H-score = 0), OR = 1.57, 95% CI = 1.06-2.33. Breast cancer specific mortality was unrelated to E-cadherin expression in multivariable models. E-cadherin low expression is associated with lobular histology, tumor characteristics and menopausal hormone use, with no evidence of an association with breast cancer specific survival. These data support loss of E-cadherin expression as an important marker of tumor subtypes.
AB - E-cadherin (CDH1) is a putative tumor suppressor gene implicated in breast carcinogenesis. Yet, whether risk factors or survival differ by E-cadherin tumor expression is unclear. We evaluated E-cadherin tumor immunohistochemistry expression using tissue microarrays of 5,933 female invasive breast cancers from 12 studies from the Breast Cancer Consortium. H-scores were calculated and case-case odds ratios (OR) and 95% confidence intervals (CIs) were estimated using logistic regression. Survival analyses were performed using Cox regression models. All analyses were stratified by estrogen receptor (ER) status and histologic subtype. E-cadherin low cases (N = 1191, 20%) were more frequently of lobular histology, low grade, >2 cm, and HER2-negative. Loss of E-cadherin expression (score < 100) was associated with menopausal hormone use among ER-positive tumors (ever compared to never users, OR = 1.24, 95% CI = 0.97-1.59), which was stronger when we evaluated complete loss of E-cadherin (i.e. H-score = 0), OR = 1.57, 95% CI = 1.06-2.33. Breast cancer specific mortality was unrelated to E-cadherin expression in multivariable models. E-cadherin low expression is associated with lobular histology, tumor characteristics and menopausal hormone use, with no evidence of an association with breast cancer specific survival. These data support loss of E-cadherin expression as an important marker of tumor subtypes.
KW - Journal Article
U2 - 10.1038/s41598-018-23733-4
DO - 10.1038/s41598-018-23733-4
M3 - SCORING: Journal article
C2 - 29700408
VL - 8
SP - 6574
JO - SCI REP-UK
JF - SCI REP-UK
SN - 2045-2322
IS - 1
ER -